|
ME00502B
(me)
|
2001-01-05 |
2011-10-10 |
Amgen Fremont Inc |
Antitjela za insulinu sličan receptor faktora i rasta
|
|
EP2295081B1
(en)
|
2001-06-26 |
2018-10-31 |
Amgen Inc. |
Antibodies to OPGL
|
|
AU2013204100A1
(en)
*
|
2001-06-26 |
2013-05-09 |
Amgen Fremont Inc. |
Antibodies to OPGL
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
US7553485B2
(en)
|
2002-01-18 |
2009-06-30 |
Pierre Fabre Medicament |
Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
|
|
FR2834990A1
(fr)
*
|
2002-01-18 |
2003-07-25 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
FR2834900B1
(fr)
*
|
2002-01-18 |
2005-07-01 |
Pf Medicament |
Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications
|
|
FR2834991B1
(fr)
*
|
2002-01-18 |
2004-12-31 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
US7241444B2
(en)
|
2002-01-18 |
2007-07-10 |
Pierre Fabre Medicament |
Anti-IGF-IR antibodies and uses thereof
|
|
US20080063639A1
(en)
*
|
2002-01-18 |
2008-03-13 |
Pierre Fabre Medicament |
Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
|
|
SI1461359T1
(sl)
*
|
2002-01-18 |
2007-06-30 |
Pf Medicament |
Nova anti IGF-IR protitelesa in njihova uporaba
|
|
US6936427B2
(en)
|
2002-02-08 |
2005-08-30 |
Trellis Bioscience, Inc. |
Real time detection of intermolecular interaction
|
|
US8658773B2
(en)
|
2011-05-02 |
2014-02-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
WO2003097805A2
(en)
|
2002-05-15 |
2003-11-27 |
California Pacific Medical Center |
Delivery of nucleic acid-like compounds
|
|
EP1506286B1
(en)
|
2002-05-24 |
2014-03-19 |
Merck Sharp & Dohme Corp. |
Neutralizing human anti-igfr antibody
|
|
US8034904B2
(en)
*
|
2002-06-14 |
2011-10-11 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
US7538195B2
(en)
|
2002-06-14 |
2009-05-26 |
Immunogen Inc. |
Anti-IGF-I receptor antibody
|
|
US7456260B2
(en)
|
2002-06-17 |
2008-11-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized antibody
|
|
AU2003275240A1
(en)
*
|
2002-09-24 |
2004-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for soluble cpg15
|
|
PL378812A1
(pl)
*
|
2003-02-13 |
2006-05-29 |
Pfizer Products Inc. |
Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
|
|
JP2007528201A
(ja)
*
|
2003-03-14 |
2007-10-11 |
ファルマシア・コーポレーション |
癌治療のためのｉｇｆ−ｉ受容体に対する抗体
|
|
CN100378127C
(zh)
*
|
2003-04-02 |
2008-04-02 |
霍夫曼-拉罗奇有限公司 |
针对胰岛素样生长因子i受体的抗体及其应用
|
|
ES2383014T3
(es)
*
|
2003-04-02 |
2012-06-15 |
F. Hoffmann-La Roche Ag |
Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
|
|
US7310537B2
(en)
*
|
2003-04-25 |
2007-12-18 |
Nokia Corporation |
Communication on multiple beams between stations
|
|
CA2524305C
(en)
|
2003-05-01 |
2015-12-08 |
Imclone Systems Incorporated |
Fully human antibodies directed against the human insulin-like growth factor-1 receptor
|
|
ATE458006T1
(de)
*
|
2003-05-14 |
2010-03-15 |
Kenta Biotech Ag |
Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa
|
|
AR046071A1
(es)
|
2003-07-10 |
2005-11-23 |
Hoffmann La Roche |
Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
|
|
US7902338B2
(en)
|
2003-07-31 |
2011-03-08 |
Immunomedics, Inc. |
Anti-CD19 antibodies
|
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
|
DE602004029581D1
(de)
*
|
2003-08-13 |
2010-11-25 |
Pfizer Prod Inc |
Modifizierte humane igf-1r antikörper
|
|
ATE492562T1
(de)
*
|
2003-09-24 |
2011-01-15 |
Kyowa Hakko Kirin Co Ltd |
Rekombinanter antikörper gegen humanen insulin- like growth factor
|
|
WO2005032476A2
(en)
*
|
2003-09-30 |
2005-04-14 |
Massachusetts Institute Of Technology |
Methods and compositions for cpg15-2
|
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
|
US7326567B2
(en)
|
2003-11-12 |
2008-02-05 |
Schering Corporation |
Plasmid system for multigene expression
|
|
TW200526684A
(en)
*
|
2003-11-21 |
2005-08-16 |
Schering Corp |
Anti-IGFR1 antibody therapeutic combinations
|
|
CN1886424A
(zh)
*
|
2003-12-08 |
2006-12-27 |
伊缪诺金公司 |
抗igf－i受体抗体
|
|
BRPI0510716A
(pt)
*
|
2004-05-05 |
2007-11-20 |
Merrimack Pharmaceuticals Inc |
uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
|
|
KR20080019733A
(ko)
*
|
2004-07-16 |
2008-03-04 |
화이자 프로덕츠 인코포레이티드 |
항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
|
|
FR2873699B1
(fr)
*
|
2004-07-29 |
2009-08-21 |
Pierre Fabre Medicament Sa |
Nouveaux anticorps anti igf ir rt leurs utilisations
|
|
PT1828249E
(pt)
|
2004-12-03 |
2011-02-25 |
Schering Corp |
Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
RU2413735C2
(ru)
|
2005-03-31 |
2011-03-10 |
Эдженсис, Инк. |
Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
|
|
JP4875064B2
(ja)
*
|
2005-04-15 |
2012-02-15 |
シェーリング コーポレイション |
癌を処置または予防するための方法および組成物
|
|
CA2763671A1
(en)
|
2005-04-26 |
2006-11-02 |
Pfizer Inc. |
P-cadherin antibodies
|
|
GB0510790D0
(en)
|
2005-05-26 |
2005-06-29 |
Syngenta Crop Protection Ag |
Anti-CD16 binding molecules
|
|
BRPI0611901A2
(pt)
*
|
2005-06-14 |
2012-08-28 |
Amgen, Inc |
composição, liofilizado, kit, e, processo para preparar uma composição
|
|
NZ564098A
(en)
*
|
2005-06-15 |
2010-04-30 |
Schering Corp |
Anti-IGF1R antibody formulations
|
|
CA2612449A1
(en)
|
2005-06-17 |
2006-12-28 |
Imclone Systems Incorporated |
Receptor antagonists for treatment of metastatic bone cancer
|
|
WO2007000328A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa |
Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
|
|
FR2888850B1
(fr)
*
|
2005-07-22 |
2013-01-11 |
Pf Medicament |
Nouveaux anticorps anti-igf-ir et leurs applications
|
|
NZ566774A
(en)
|
2005-09-07 |
2011-11-25 |
Pfizer |
Human monoclonal antibodies to activin receptor-like kinase-1
|
|
CN100445300C
(zh)
*
|
2005-09-30 |
2008-12-24 |
李玉新 |
Glp-1融合蛋白及其制备方法和医药用途
|
|
EP1957541A2
(en)
|
2005-11-21 |
2008-08-20 |
Laboratoires Serono SA |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
DK1979001T3
(da)
|
2005-12-13 |
2012-07-16 |
Medimmune Ltd |
Bindingsproteiner, der er specifikke for insulinlignende vækstfaktorer og anvendelser deraf
|
|
AR060017A1
(es)
|
2006-01-13 |
2008-05-21 |
Novartis Ag |
Composiciones y metodos de uso para anticuerpos de dickkopf -1
|
|
WO2007084631A2
(en)
|
2006-01-20 |
2007-07-26 |
Cell Signaling Technology, Inc. |
Translocation and mutant ros kinase in human non-small cell lung carcinoma
|
|
US20120208824A1
(en)
|
2006-01-20 |
2012-08-16 |
Cell Signaling Technology, Inc. |
ROS Kinase in Lung Cancer
|
|
AP2008004569A0
(en)
|
2006-02-03 |
2008-08-31 |
Imclone Systems Inc |
IGR-IR antagonists as adjuvants for treatment of prostrate cancer
|
|
WO2007095113A2
(en)
*
|
2006-02-10 |
2007-08-23 |
Massachusetts Institute Of Technology |
Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
|
|
JP2009531371A
(ja)
*
|
2006-03-28 |
2009-09-03 |
エフ．ホフマン−ラ ロシュ アーゲー |
抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
|
|
AU2007245164A1
(en)
|
2006-03-28 |
2007-11-08 |
Biogen Idec Ma Inc. |
Anti-IGF-IR antibodies and uses thereof
|
|
US7846724B2
(en)
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
|
PT2450437T
(pt)
|
2006-04-14 |
2017-08-25 |
Cell Signaling Technology Inc |
Defeitos de genes e cinase alk mutante em tumores sólidos humanos
|
|
EP2258700A1
(en)
|
2006-05-09 |
2010-12-08 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
|
WO2008005469A2
(en)
|
2006-06-30 |
2008-01-10 |
Schering Corporation |
Igfbp2 biomarker
|
|
EP2104501B1
(en)
|
2006-12-13 |
2014-03-12 |
Merck Sharp & Dohme Corp. |
Methods of cancer treatment with igf1r inhibitors
|
|
AR064464A1
(es)
*
|
2006-12-22 |
2009-04-01 |
Genentech Inc |
Anticuerpos anti - receptor del factor de crecimiento insulinico
|
|
GB0702888D0
(en)
*
|
2007-02-14 |
2007-03-28 |
Glaxo Group Ltd |
Novel Antibodies
|
|
JP2010518140A
(ja)
*
|
2007-02-14 |
2010-05-27 |
グラクソ グループ リミテッド |
Ｉｇｆ−１ｒに対する新規抗体
|
|
ATE530907T1
(de)
*
|
2007-02-27 |
2011-11-15 |
Hoffmann La Roche |
Verfahren zur beurteilung der hemmungsaktivität von antikörpern gegen insulinartigen wachstumsfaktor-1-rezeptor
|
|
AU2008223541B2
(en)
*
|
2007-03-02 |
2012-04-05 |
Amgen Inc. |
Methods and compositions for treating tumor diseases
|
|
US8642067B2
(en)
|
2007-04-02 |
2014-02-04 |
Allergen, Inc. |
Methods and compositions for intraocular administration to treat ocular conditions
|
|
AU2008239594B2
(en)
|
2007-04-13 |
2013-10-24 |
Beth Israel Deaconess Medical Center |
Methods for treating cancer resistant to ErbB therapeutics
|
|
EP2559771A3
(en)
|
2007-05-17 |
2013-06-12 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
|
|
PE20090368A1
(es)
|
2007-06-19 |
2009-04-28 |
Boehringer Ingelheim Int |
Anticuerpos anti-igf
|
|
KR20100052545A
(ko)
*
|
2007-08-28 |
2010-05-19 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
|
|
CA2697612A1
(en)
*
|
2007-08-28 |
2009-03-12 |
Biogen Idec Ma Inc. |
Anti-igf-1r antibodies and uses thereof
|
|
MX2010002249A
(es)
*
|
2007-08-31 |
2010-03-17 |
Amgen Inc |
Formulacion de proteina de estado solido.
|
|
EP2205280B1
(en)
*
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
|
JP5769968B2
(ja)
|
2007-10-18 |
2015-08-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ
|
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
|
PT2594590E
(pt)
|
2007-12-14 |
2015-01-14 |
Bristol Myers Squibb Co |
Moléculas de ligação ao recetor humano ox40
|
|
ES2388017T3
(es)
|
2007-12-21 |
2012-10-05 |
Roche Glycart Ag |
Ensayo de estabilidad de anticuerpos
|
|
US20110104256A1
(en)
*
|
2008-03-25 |
2011-05-05 |
Yaolin Wang |
Methods for treating or preventing colorectal cancer
|
|
SG190572A1
(en)
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
TW201006485A
(en)
|
2008-06-03 |
2010-02-16 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
|
CN102149825B
(zh)
|
2008-07-08 |
2015-07-22 |
Abbvie公司 |
前列腺素e2双重可变结构域免疫球蛋白及其用途
|
|
JP5576370B2
(ja)
|
2008-08-06 |
2014-08-20 |
ファイザー・インク |
Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
|
|
NZ597692A
(en)
|
2008-12-12 |
2013-08-30 |
Boehringer Ingelheim Int |
Anti-IGF antibodies
|
|
EP3266795A1
(en)
|
2009-02-12 |
2018-01-10 |
Cell Signaling Technology, Inc. |
Method for detecting a fig-ros fusion polynucleotide
|
|
US20160095939A1
(en)
|
2014-10-07 |
2016-04-07 |
Immunomedics, Inc. |
Neoadjuvant use of antibody-drug conjugates
|
|
ES3000111T3
(en)
|
2009-02-13 |
2025-02-27 |
Immunomedics Inc |
Intermediates for preparing conjugates with an intracellularly-cleavable linkage
|
|
EP2236139A1
(en)
|
2009-03-31 |
2010-10-06 |
F. Hoffmann-La Roche AG |
Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
|
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
|
WO2010120599A2
(en)
|
2009-04-16 |
2010-10-21 |
Merck Sharp & Dohme Corp. |
Compositions and methods for treating cancer
|
|
PE20120532A1
(es)
*
|
2009-04-27 |
2012-05-18 |
Novartis Ag |
ANTICUERPOS ANTI-ActRIIB
|
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
|
DK3622815T3
(da)
|
2009-07-08 |
2023-06-26 |
Kymab Ltd |
Gnavermodeller og terapeutiske molekyler
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2011028811A2
(en)
|
2009-09-01 |
2011-03-10 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
BR112012008833A2
(pt)
|
2009-10-15 |
2015-09-08 |
Abbott Lab |
imunoglobulinas de dominio variavel duplo e usos das mesmas
|
|
WO2011050333A1
(en)
|
2009-10-23 |
2011-04-28 |
Amgen Inc. |
Vial adapter and system
|
|
SI2493922T1
(sl)
|
2009-10-26 |
2017-06-30 |
F. Hoffmann-La Roche Ag |
Postopek za proizvodnjo glikoziliranega imunoglobulina
|
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
|
EP2494070A2
(en)
|
2009-10-30 |
2012-09-05 |
Bristol-Myers Squibb Company |
Methods for treating cancer in patients having igf-1r inhibitor resistance
|
|
ES2978177T3
(es)
|
2009-12-02 |
2024-09-06 |
Immunomedics Inc |
Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
|
|
WO2011083391A2
(en)
|
2010-01-05 |
2011-07-14 |
Pfizer Inc. |
Biomarkers for anti-igf-ir cancer therapy
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
|
EP2571992B1
(en)
|
2010-05-21 |
2018-04-25 |
Merrimack Pharmaceuticals, Inc. |
Bi-specific fusion proteins
|
|
SG186094A1
(en)
|
2010-06-07 |
2013-01-30 |
Amgen Inc |
Drug delivery device
|
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
|
RU2012157167A
(ru)
|
2010-07-12 |
2014-08-20 |
КовЭкс Текнолоджиз Айэлэнд Лимитед |
Полифункциональные антительные конъюгаты
|
|
EP3252072A3
(en)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
|
US20120101108A1
(en)
|
2010-08-06 |
2012-04-26 |
Cell Signaling Technology, Inc. |
Anaplastic Lymphoma Kinase In Kidney Cancer
|
|
JP2013539364A
(ja)
|
2010-08-26 |
2013-10-24 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリンおよびその使用
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
RU2607033C2
(ru)
*
|
2010-09-28 |
2017-01-10 |
Ноно Инк. |
Пептиды nd2 и способы лечения неврологического заболевания
|
|
EP3974453A3
(en)
*
|
2010-11-16 |
2022-08-03 |
Amgen Inc. |
Agents and methods for treating diseases that correlate with bcma expression
|
|
EP2643694B1
(en)
|
2010-11-24 |
2018-01-03 |
Litron Laboratories Ltd. |
Rapid in vivo gene mutation assay based on the pig-a gene
|
|
MX2013008833A
(es)
|
2011-02-02 |
2013-12-06 |
Amgen Inc |
Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
|
|
KR20130118941A
(ko)
|
2011-02-10 |
2013-10-30 |
로슈 글리카트 아게 |
면역치료법
|
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
|
CN103561771B
(zh)
|
2011-03-17 |
2019-01-04 |
伯明翰大学 |
重新定向的免疫治疗
|
|
MY171008A
(en)
|
2011-03-29 |
2019-09-23 |
Immunogen Inc |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
ME03353B
(me)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
AU2012236573B2
(en)
|
2011-03-31 |
2016-06-02 |
Amgen Inc. |
Vial adapter and system
|
|
US8476409B2
(en)
*
|
2011-04-19 |
2013-07-02 |
Merrimack Pharmaceuticals, Inc. |
Bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
HUE042822T2
(hu)
|
2011-04-20 |
2019-07-29 |
Amgen Inc |
Automata befecskendezõ szerkezet
|
|
HUE047278T2
(hu)
|
2011-08-05 |
2020-04-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
EP2766497A1
(en)
|
2011-10-13 |
2014-08-20 |
Bristol-Myers Squibb Company |
Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors
|
|
PL3045187T3
(pl)
|
2011-10-14 |
2019-09-30 |
Amgen Inc. |
Wstrzykiwacz i sposób montażu
|
|
US20130122005A1
(en)
*
|
2011-10-27 |
2013-05-16 |
Paul Adam |
Anticancer combination therapy
|
|
EP3559049B1
(en)
|
2011-10-28 |
2025-06-11 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptide constructs and uses thereof
|
|
WO2013071056A2
(en)
|
2011-11-11 |
2013-05-16 |
Duke University |
Combination drug therapy for the treatment of solid tumors
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
KR101470700B1
(ko)
*
|
2011-11-25 |
2014-12-12 |
서울대학교산학협력단 |
표적 항암제의 내성 극복 방법
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
US9997847B2
(en)
|
2011-12-27 |
2018-06-12 |
Perfectvision Manufacturing, Inc. |
Coaxial Connector with grommet biasing for enhanced continuity
|
|
TW201333035A
(zh)
|
2011-12-30 |
2013-08-16 |
Abbvie Inc |
針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
|
|
EP2631653A1
(en)
|
2012-02-24 |
2013-08-28 |
Charité - Universitätsmedizin Berlin |
Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
PL2838998T3
(pl)
|
2012-04-18 |
2018-04-30 |
Cell Signaling Technology, Inc. |
EGFR i ROS1 w nowotworze
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
CA2875543A1
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind igf1r
|
|
EP3539563A1
(en)
|
2012-07-19 |
2019-09-18 |
Redwood Bioscience, Inc. |
Antibody specific for cd22 and methods of use thereof
|
|
US8980259B2
(en)
|
2012-07-20 |
2015-03-17 |
Novartis Ag |
Combination therapy
|
|
MY175687A
(en)
|
2012-08-07 |
2020-07-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
|
CN104379169A
(zh)
|
2012-08-14 |
2015-02-25 |
Ibc药品公司 |
用于治疗疾病的t-细胞重定向双特异性抗体
|
|
RU2661083C2
(ru)
|
2012-10-04 |
2018-07-11 |
Иммуноджен, Инк. |
Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
|
|
TW202037609A
(zh)
|
2012-11-01 |
2020-10-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
|
ES2860954T3
(es)
|
2012-11-21 |
2021-10-05 |
Amgen Inc |
Dispositivo de administración de fármacos
|
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
|
MX359651B
(es)
|
2012-11-29 |
2018-10-05 |
Chemocentryx Inc |
Antagonistas de cxcr7.
|
|
WO2017004144A1
(en)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
HK1220465A1
(zh)
|
2013-03-06 |
2017-05-05 |
Merrimack Pharmaceuticals, Inc. |
抗c-met串联fc双特异性抗体
|
|
US20140255413A1
(en)
|
2013-03-07 |
2014-09-11 |
Boehringer Ingelheim International Gmbh |
Combination therapy for neoplasia treatment
|
|
TWI614041B
(zh)
|
2013-03-15 |
2018-02-11 |
安美基公司 |
用於注射器之匣盒
|
|
US10646664B2
(en)
|
2013-03-15 |
2020-05-12 |
Amgen Inc. |
Body contour adaptable autoinjector device
|
|
US9708375B2
(en)
|
2013-03-15 |
2017-07-18 |
Amgen Inc. |
Inhibitory polypeptides specific to WNT inhibitors
|
|
WO2014144280A2
(en)
|
2013-03-15 |
2014-09-18 |
Abbvie Inc. |
DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
|
|
JP6336564B2
(ja)
|
2013-03-15 |
2018-06-06 |
アムゲン・インコーポレーテッド |
薬物カセット、自動注入器、および自動注入器システム
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
WO2014149357A1
(en)
|
2013-03-22 |
2014-09-25 |
Amgen Inc. |
Injector and method of assembly
|
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
|
BR112015027313A2
(pt)
|
2013-04-29 |
2017-09-26 |
Teva Pharmaceuticals Australia Pty Ltd |
anticorpos anti-cd38 e fusões ao interferon alfa-2b atenuado
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
JP6869720B2
(ja)
*
|
2013-06-13 |
2021-05-12 |
アンチセンス セラピューティクス リミテッド |
併用療法
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
EP3041863A4
(en)
|
2013-09-05 |
2017-08-16 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
CA3168888A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Drug delivery system with temperature-sensitive control
|
|
SG11201602876WA
(en)
|
2013-10-24 |
2016-05-30 |
Amgen Inc |
Injector and method of assembly
|
|
CA2936675C
(en)
|
2014-01-12 |
2023-06-27 |
Igf Oncology, Llc |
Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
|
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
|
JP6447933B2
(ja)
|
2014-02-21 |
2019-01-09 |
アイビーシー ファーマスーティカルズ，インコーポレイテッド |
Ｔｒｏｐ−２発現細胞に対する免疫応答を誘発することによる疾患治療
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
AU2015256082C1
(en)
|
2014-05-07 |
2020-09-10 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
|
US10156562B2
(en)
|
2014-05-16 |
2018-12-18 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
|
CN111840696B
(zh)
|
2014-06-03 |
2022-12-20 |
安姆根有限公司 |
可控制药物递送系统和使用方法
|
|
EP3160504B1
(en)
|
2014-06-24 |
2020-09-16 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
EP3206739B1
(en)
|
2014-10-14 |
2021-12-01 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
|
US10544199B2
(en)
|
2014-10-29 |
2020-01-28 |
Teva Pharmaceuticals Australia Pty Ltd |
Interferon alpha 2B variants
|
|
US10413615B2
(en)
|
2014-11-19 |
2019-09-17 |
Immunogen, Inc. |
Process for preparing cell-binding agent-cytotoxic agent conjugates
|
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
|
US11357916B2
(en)
|
2014-12-19 |
2022-06-14 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
|
EP3848072A1
(en)
|
2014-12-19 |
2021-07-14 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
|
JP6484345B2
(ja)
|
2015-02-17 |
2019-03-20 |
アムジエン・インコーポレーテツド |
固定及び／または戻りが真空によって支援された薬物送達装置
|
|
KR20180016972A
(ko)
*
|
2015-02-22 |
2018-02-20 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Cd137에 결합하는 항체 치료제
|
|
WO2016138434A1
(en)
|
2015-02-27 |
2016-09-01 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
AU2016252771B2
(en)
|
2015-04-22 |
2021-12-16 |
Immunomedics, Inc. |
Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
|
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
|
|
JP6980980B2
(ja)
|
2015-06-25 |
2021-12-15 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
|
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
|
CN108367048B
(zh)
|
2015-10-02 |
2022-08-12 |
银溪制药股份有限公司 |
用于组织修复的双特异性治疗性蛋白质
|
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
|
EP3373937B1
(en)
|
2015-11-09 |
2021-12-22 |
R.P. Scherer Technologies, LLC |
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
|
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
|
US11154661B2
(en)
|
2016-01-06 |
2021-10-26 |
Amgen Inc. |
Auto-injector with signaling electronics
|
|
TW201731532A
(zh)
|
2016-02-05 |
2017-09-16 |
伊繆諾金公司 |
用於製備細胞結合劑-細胞毒性劑結合物之有效方法
|
|
CN116284392A
(zh)
|
2016-03-10 |
2023-06-23 |
艾科赛扬制药股份有限公司 |
活化素2型受体结合蛋白及其用途
|
|
DK3429663T3
(da)
|
2016-03-15 |
2020-09-28 |
Amgen Inc |
Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
|
|
WO2017189089A1
(en)
|
2016-04-29 |
2017-11-02 |
Amgen Inc. |
Drug delivery device with messaging label
|
|
US11389588B2
(en)
|
2016-05-02 |
2022-07-19 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
|
AU2017263558B2
(en)
|
2016-05-13 |
2022-12-22 |
Amgen Inc. |
Vial sleeve assembly
|
|
WO2017200989A1
(en)
|
2016-05-16 |
2017-11-23 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
|
US11541176B2
(en)
|
2016-06-03 |
2023-01-03 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
|
EP3478342B1
(en)
|
2016-07-01 |
2025-03-12 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
|
PT3528787T
(pt)
|
2016-10-21 |
2026-03-11 |
Amgen Inc |
Formulações farmacêuticas e métodos para produzir as mesmas
|
|
US20200261643A1
(en)
|
2016-10-25 |
2020-08-20 |
Amgen Inc. |
On-body injector
|
|
CN108084262A
(zh)
*
|
2016-11-23 |
2018-05-29 |
复旦大学 |
针对寨卡病毒的全人源单域抗体或抗原结合片段及应用
|
|
BR112019013953A2
(pt)
|
2017-01-06 |
2020-02-11 |
Abl Bio Inc. |
Anticorpo anti-a-syn e uso do mesmo
|
|
AU2018210301A1
(en)
|
2017-01-17 |
2019-08-01 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
|
CA3052204A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
WO2018151890A1
(en)
|
2017-02-17 |
2018-08-23 |
Amgen Inc. |
Drug delivery device with sterile fluid flowpath and related method of assembly
|
|
EP3592403B1
(en)
|
2017-03-06 |
2025-08-20 |
Amgen Inc. |
Drug delivery device with activation prevention feature
|
|
US11571511B2
(en)
|
2017-03-07 |
2023-02-07 |
Amgen Inc. |
Insertion mechanism and method of inserting a needle of a drug delivery device
|
|
AU2018230486B2
(en)
|
2017-03-09 |
2023-05-11 |
Amgen Inc. |
Insertion mechanism for drug delivery device
|
|
CA3056011A1
(en)
|
2017-03-14 |
2018-09-20 |
Amgen Inc. |
Control of total afucosylated glycoforms of antibodies produced in cell culture
|
|
ES3023742T3
(en)
|
2017-03-28 |
2025-06-03 |
Amgen Inc |
Plunger rod and syringe assembly system
|
|
CN117442747A
(zh)
|
2017-05-21 |
2024-01-26 |
Igf肿瘤公司 |
胰岛素样生长因子——用于治疗骨髓增生异常综合症的化学治疗缀合物
|
|
US11590294B2
(en)
|
2017-06-08 |
2023-02-28 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
|
JP7200134B2
(ja)
|
2017-06-08 |
2023-01-06 |
アムジエン・インコーポレーテツド |
トルク駆動式薬物送達デバイス
|
|
JP7195276B2
(ja)
|
2017-06-22 |
2022-12-23 |
アムジエン・インコーポレーテツド |
デバイス起動による衝突／衝撃の低減
|
|
WO2018237225A1
(en)
|
2017-06-23 |
2018-12-27 |
Amgen Inc. |
Electronic drug delivery device comprising a cap activated by a switch assembly
|
|
IL270784B2
(en)
|
2017-07-14 |
2023-11-01 |
Amgen Inc |
Needle insertion-extraction system with a double torsion spring system
|
|
JP7649105B2
(ja)
|
2017-07-21 |
2025-03-19 |
アムジエン・インコーポレーテツド |
薬物容器のためのガス透過性シーリング部材及び組立方法
|
|
US11617837B2
(en)
|
2017-07-25 |
2023-04-04 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
|
MA49676A
(fr)
|
2017-07-25 |
2020-06-03 |
Amgen Inc |
Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
|
|
MA49838A
(fr)
|
2017-08-09 |
2020-06-17 |
Amgen Inc |
Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
|
|
EP3668567B1
(en)
|
2017-08-18 |
2026-02-18 |
Amgen Inc. |
Wearable injector with sterile adhesive patch
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
|
US20210332141A1
(en)
|
2017-08-30 |
2021-10-28 |
Amgen Inc. |
Insulin-like growth factor-1 receptor (igf-1r) binding proteins and methods of use
|
|
WO2019070472A1
(en)
|
2017-10-04 |
2019-04-11 |
Amgen Inc. |
FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE
|
|
ES2971450T3
(es)
|
2017-10-06 |
2024-06-05 |
Amgen Inc |
Dispositivo de administración de fármacos con conjunto de enclavamiento y procedimiento de montaje correspondiente
|
|
US11464903B2
(en)
|
2017-10-09 |
2022-10-11 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
|
CN111885914B
(zh)
*
|
2017-10-27 |
2022-05-13 |
投资健康有限责任公司 |
使用芴衍生物制造扩增的造血干细胞的组合物和方法
|
|
IL273582B2
(en)
|
2017-11-03 |
2024-12-01 |
Amgen Inc |
Systems and approaches for sterilizing a drug delivery device
|
|
EP3707075A1
(en)
|
2017-11-06 |
2020-09-16 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
|
EP3706830B1
(en)
|
2017-11-06 |
2024-08-07 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
|
MA50557A
(fr)
|
2017-11-10 |
2020-09-16 |
Amgen Inc |
Pistons pour dispositifs d'administration de médicament
|
|
MX2020005066A
(es)
|
2017-11-16 |
2020-08-20 |
Amgen Inc |
Autoinyector con deteccion de detencion y punto final.
|
|
JP7370969B2
(ja)
|
2017-11-16 |
2023-10-30 |
アムジエン・インコーポレーテツド |
薬物送達デバイスの扉ラッチ機構
|
|
EP3725806A4
(en)
|
2017-12-14 |
2022-03-30 |
ABL Bio Inc. |
BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
|
|
WO2019148444A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Anti-ctla4 antibodies and methods of making and using the same
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
US12325737B2
(en)
|
2018-03-26 |
2025-06-10 |
Amgen Inc. |
Total afucosylated glycoforms of antibodies produced in cell culture
|
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
|
US12303677B2
(en)
|
2018-07-24 |
2025-05-20 |
Amgen Inc. |
Hybrid drug delivery devices with optional grip portion and related method of preparation
|
|
CA3103681A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Delivery devices for administering drugs
|
|
MA53375A
(fr)
|
2018-07-24 |
2021-06-02 |
Amgen Inc |
Dispositifs d'administration pour l'administration de médicaments
|
|
CA3103105A1
(en)
|
2018-07-31 |
2020-02-06 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
|
US20210346601A1
(en)
|
2018-09-24 |
2021-11-11 |
Amgen Inc. |
Interventional dosing systems and methods
|
|
CA3110371A1
(en)
|
2018-09-28 |
2020-04-02 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
|
EP3860685A1
(en)
|
2018-10-02 |
2021-08-11 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
|
US12151089B2
(en)
|
2018-10-05 |
2024-11-26 |
Amgen Inc. |
Drug delivery device having dose indicator
|
|
TW202541859A
(zh)
|
2018-10-15 |
2025-11-01 |
美商安進公司 |
具有阻尼機構之藥物遞送裝置及自動注射器
|
|
WO2020081480A1
(en)
|
2018-10-15 |
2020-04-23 |
Amgen Inc. |
Platform assembly process for drug delivery device
|
|
MA54048A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament avec rétraction partielle de l'organe d'administration de médicament
|
|
EP3873563A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
|
TWI831847B
(zh)
|
2018-11-01 |
2024-02-11 |
美商安進公司 |
部分針頭縮回之藥物遞送裝置及其操作方法
|
|
BR112021010479A2
(pt)
*
|
2018-12-03 |
2021-11-16 |
Teijin Pharma Ltd |
Anticorpo humanizado anti-receptor de igf-i ou fragmento ou derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo para produção de um anticorpo humanizado anti-receptor de igf-i ou fragmento ou derivado do mesmo, e, composição farmacêutica
|
|
MX2021006915A
(es)
|
2018-12-12 |
2021-08-24 |
Chemocentryx Inc |
Inhibidores de cxcr7 para el tratamiento de cancer.
|
|
EP3897851A2
(en)
|
2018-12-17 |
2021-10-27 |
Revitope Limited |
Twin immune cell engager
|
|
AU2020263289B2
(en)
|
2019-04-24 |
2025-05-22 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
|
AU2020275413A1
(en)
|
2019-05-14 |
2021-12-23 |
Cedars-Sinai Medical Center |
TL1A patient selection methods, systems, and devices
|
|
WO2021041067A2
(en)
|
2019-08-23 |
2021-03-04 |
Amgen Inc. |
Drug delivery device with configurable needle shield engagement components and related methods
|
|
AU2020337958A1
(en)
|
2019-08-28 |
2022-03-17 |
Horizon Therapeutics Ireland Dac |
Methods for the treatment of thyroid eye disease
|
|
BR112022005583A2
(pt)
|
2019-09-26 |
2022-09-20 |
Amgen Inc |
Métodos para a produção de composições de anticorpos
|
|
EP4559477A3
(en)
|
2020-05-13 |
2025-08-13 |
Adagene AG |
Compositions and methods for treating cancer
|
|
US20230273126A1
(en)
|
2020-06-04 |
2023-08-31 |
Amgen Inc. |
Assessment of cleaning procedures of a biotherapeutic manufacturing process
|
|
US20220267450A1
(en)
|
2020-10-14 |
2022-08-25 |
Viridian Therapeutics, Inc. |
Compositions and methods for treatment of thyroid eye disease
|
|
KR20230087539A
(ko)
|
2020-10-15 |
2023-06-16 |
암젠 인크 |
항체 생산 방법에서의 상대적인 비결합 글리칸
|
|
JP2024503933A
(ja)
|
2021-01-27 |
2024-01-29 |
イノベント バイオロジクス（スーチョウ）カンパニー，リミティド |
Ｃｄ１６ａに対する単一ドメイン抗体およびその使用
|
|
US20240166760A1
(en)
*
|
2021-03-08 |
2024-05-23 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
MOLECULES THAT BIND TO CD66e POLYPEPTIDES
|
|
CN112794912B
(zh)
*
|
2021-04-14 |
2021-07-06 |
苏州普乐康医药科技有限公司 |
一种抗igf-1r抗体及其应用
|
|
WO2022239720A1
(ja)
|
2021-05-10 |
2022-11-17 |
公益財団法人川崎市産業振興財団 |
抗原への結合親和性を低減させた抗体
|
|
JP2024523779A
(ja)
|
2021-05-21 |
2024-07-02 |
アムジェン インコーポレイテッド |
薬物容器用の充填レシピを最適化する方法
|
|
EP4352094A1
(en)
|
2021-06-07 |
2024-04-17 |
Amgen Inc. |
Using fucosidase to control afucosylation level of glycosylated proteins
|
|
EP4384219A4
(en)
|
2021-08-10 |
2025-06-18 |
Viridian Therapeutics, Inc. |
COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
|
|
US20250076309A1
(en)
|
2021-10-05 |
2025-03-06 |
Amgen Inc. |
Fc-gamma receptor ii binding and glycan content
|
|
KR20240135670A
(ko)
*
|
2022-01-29 |
2024-09-11 |
밍훼이 파마슈티컬 (항저우) 리미티드 |
항원 결합 단백질 및 이의 용도
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
AU2024244149A1
(en)
*
|
2023-04-04 |
2025-08-28 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Anti-igf1r antibodies and uses thereof
|
|
AU2024256160A1
(en)
|
2023-04-20 |
2025-10-02 |
Amgen Inc. |
Methods of determining relative unpaired glycan content
|
|
AU2024287547A1
(en)
|
2023-07-07 |
2026-01-22 |
Viridian Therapeutics, Inc. |
Methods of treating chronic thyroid eye disease
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
CN117079823B
(zh)
*
|
2023-10-17 |
2024-01-02 |
北京大学第三医院（北京大学第三临床医学院） |
早期预测选择性胎儿生长受限发病风险筛查的系统和方法
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2026030152A1
(en)
|
2024-07-29 |
2026-02-05 |
Amgen Inc. |
System and method for assessing transferability of a fill recipe
|